Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Аннотация
BACKGROUND/AIM: Docetaxel, cisplatin, and 5-fluorouracil (DCF) have been established as a standard neoadjuvant chemotherapy regimen for resectable esophageal squamous cell carcinoma (ESCC); however, the substantial toxicity of this regimen may limit its use in clinical practice. Therefore, a biweekly divided-dose DCF regimen (Bi-DCF) has been developed to improve tolerability while maintaining dose intensity. This study aimed to evaluate the safety and feasibility of preoperative Bi-DCF in a real-world clinical setting.
PATIENTS AND
METHODS
This retrospective single-institution study included 63 patients with ESCC who had received preoperative Bi-DCF between January 2016 and December 2020. Patients were stratified by age (≤75 years and ≥76 years), and age-based comparisons were performed as exploratory analyses. The primary endpoint was the incidence of grade ≥3 adverse events. Secondary endpoints included treatment feasibility, as assessed by the average relative dose intensity (ARDI), surgical outcomes, pathological responses, and recurrence-free survival (RFS).
RESULTS
Grade ≥3 adverse events occurred in 44.4% of patients. Non-hematological toxicities were generally infrequent, and severe renal dysfunction occurred in only two patients. No treatment-related mortality occurred. In exploratory analyses, no apparent differences in the incidence of grade ≥3 adverse events were observed between age groups. The median ARDI was 100% (range=33.3-100%) in the overall cohort and was maintained across age groups. Exploratory analyses did not demonstrate clear differences in RFS between age groups; however, these findings should be interpreted with caution because of the limited number of elderly patients.
CONCLUSION
Biweekly divided-dose DCF appears to be a feasible and tolerable neoadjuvant regimen for ESCC, with preserved dose intensity and acceptable perioperative outcomes in a real-world clinical setting. This regimen may represent a practical alternative for selected patients who are not suitable candidates for standard-dose DCF, although prospective validation in larger cohorts is warranted.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.